About Dr. Zhu Zhengfei
Dr. Zhu Zhengfei (朱正飞) is the Director of the Department of Radiation Oncology at Huashan Hospital, Fudan University — one of Shanghai's leading academic radiation oncology centers. A nationally recognized authority in thoracic radiation oncology, Dr. Zhu specializes in the precise, image-guided radiotherapy of lung cancer, esophageal cancer, head and neck cancers, and brain tumors, with particular expertise in stereotactic body radiotherapy (SBRT), stereotactic radiosurgery (SRS), and intensity-modulated radiotherapy (IMRT).
Dr. Zhu is known for his technical precision, his commitment to minimizing treatment toxicity while maximizing tumor control, and his leadership in integrating radiotherapy with systemic therapy — including concurrent chemoradiation and immunotherapy combinations — to achieve optimal outcomes for patients with locally advanced and oligometastatic disease. His multidisciplinary approach brings together radiation oncology, medical oncology, thoracic surgery, and neurosurgery to deliver coordinated, evidence-based cancer care.
Hospital Affiliation
Huashan Hospital, Fudan University is consistently ranked among China's top hospitals. Its radiation oncology department is equipped with state-of-the-art linear accelerators including TrueBeam and Varian Edge systems capable of SBRT, SRS, VMAT, and adaptive radiotherapy. The department operates a dedicated radiosurgery program for brain metastases and primary brain tumors, and has a strong track record in the radiotherapy of thoracic malignancies — benefiting from close collaboration with Huashan's thoracic surgery and medical oncology teams.
Clinical Expertise
- Lung cancer radiotherapy — SBRT for early-stage NSCLC; concurrent chemoradiation for locally advanced NSCLC; prophylactic cranial irradiation for SCLC; oligometastatic disease consolidation
- Esophageal cancer — definitive and neoadjuvant chemoradiation; IMRT for dose escalation and toxicity reduction
- Head & neck cancers — IMRT for nasopharyngeal carcinoma, oropharyngeal cancer, laryngeal cancer; salivary gland sparing; re-irradiation protocols
- Brain tumors & metastases — SRS/SRT for brain metastases (single and multiple); whole brain radiotherapy with hippocampal avoidance; glioblastoma radiotherapy; meningioma SRS
- Stereotactic body radiotherapy (SBRT) — lung, liver, spine, adrenal, and oligometastatic disease; ablative dose protocols
- Stereotactic radiosurgery (SRS) — brain metastases, arteriovenous malformations (AVMs), trigeminal neuralgia, acoustic neuroma
- Thoracic malignancies — thymoma, mesothelioma, chest wall tumors; post-operative radiotherapy coordination
- Immunotherapy + radiotherapy combinations — abscopal effect optimization; checkpoint inhibitor sequencing with radiotherapy
- Re-irradiation — recurrent head and neck cancer, recurrent lung cancer, spinal cord tolerance management
- Palliative radiotherapy — bone metastases, spinal cord compression, superior vena cava syndrome, hemostatic radiotherapy
Academic & Research Contributions
Dr. Zhu Zhengfei has authored numerous peer-reviewed publications in leading radiation oncology and oncology journals including the International Journal of Radiation Oncology, Biology, Physics (Red Journal), Radiotherapy and Oncology, and Journal of Thoracic Oncology. His research focuses on the optimization of SBRT dose and fractionation for thoracic malignancies, the integration of immunotherapy with radiotherapy, and the management of radiation-induced toxicities in lung and esophageal cancer patients.
He is an active member of the Chinese Society of Radiation Oncology (CSTRO) and has contributed to the development of national clinical guidelines for lung cancer and esophageal cancer radiotherapy. Dr. Zhu has served as principal investigator on multicenter clinical trials evaluating SBRT protocols and immunotherapy-radiotherapy combinations, and is a regular presenter at ASTRO, ESTRO, and CSTRO annual meetings.
His work on SBRT for oligometastatic NSCLC — including the use of ablative radiotherapy to delay systemic therapy initiation and prolong progression-free survival — has been particularly influential in shaping the management of this increasingly recognized disease state in Chinese patients.
Why International Patients Choose Dr. Zhu Zhengfei
International patients seek Dr. Zhu's expertise for access to advanced radiotherapy techniques — including SBRT and SRS — that may not be available or affordable in their home countries, second opinions on radiotherapy planning for complex cases, and management of recurrent or oligometastatic disease where ablative radiotherapy may offer a curative or disease-controlling option.
The cost advantage is substantial: SBRT, SRS, and IMRT at Huashan Hospital are available at a fraction of the cost of equivalent treatment in the United States or Australia, with no compromise in equipment quality, treatment planning sophistication, or clinical expertise. For patients facing high out-of-pocket radiotherapy costs at home, this can make a meaningful difference in their ability to access optimal treatment.
CMCS coordinates all aspects of the radiotherapy consultation, from medical record and imaging translation to treatment planning review and remote follow-up support after patients return home.
What to Expect at Your Consultation
Consultations with Dr. Zhu begin with a comprehensive review of pathology, prior imaging, treatment history, and any previous radiotherapy records. CMCS will arrange certified translation of all records and imaging in advance. Dr. Zhu will provide a detailed radiotherapy plan including technique selection, dose and fractionation, expected toxicity profile, and integration with systemic therapy — all summarized in English for your home oncologist or radiation oncologist.
For patients proceeding to treatment at Huashan, the planning process typically takes 3–5 days including simulation CT, treatment planning, and quality assurance verification. CMCS coordinates all logistics including accommodation, hospital registration, and daily transport to and from the treatment center.
Frequently Asked Questions
Is SBRT available at Huashan for lung and liver tumors?
Yes. Huashan's radiation oncology department has extensive experience with SBRT for early-stage lung cancer, oligometastatic lung and liver disease, and spinal metastases, using state-of-the-art linear accelerators with real-time image guidance.
Can Dr. Zhu review my existing radiotherapy plan for a second opinion?
Yes. Second-opinion consultations on radiotherapy planning are available. CMCS will arrange translation of your imaging and treatment records and coordinate a review appointment with Dr. Zhu.
How long does a course of SBRT take?
SBRT is typically delivered in 3–5 fractions over 1–2 weeks, making it feasible for international patients to complete a full course during a single visit to Shanghai. CMCS will plan your itinerary accordingly.
Book a Consultation Through CMCS
China Medical Concierge Shanghai (CMCS) provides end-to-end support for international patients seeking radiation oncology care with Dr. Zhu Zhengfei at Huashan Hospital, including priority appointment scheduling, certified medical translation, imaging review coordination, treatment logistics, and post-treatment follow-up. Contact us at contract@medicalsh.com, or visit medicalsh.com.
0 則留言